Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

231 children with metastatic neuroblastoma prospectively followed up in three clinical trials underwent first look surgery at diagnosis or delayed first look operation after application of chemotherapy and partly second look surgery and were evaluated for resectability and complication rate. More than 85% of the primary tumours were located within the abdomen. The incidence of macroscopically complete removal increased from 30% to 60% after preoperative chemotherapy (p less than 0.001). There was no difference between the efficacy of delayed first look and second look surgery and between children with stage IV and stage IV S neuroblastoma. The mean complication rate was 20% (complication per patient) and 23% (complication per operation). Complications included local problems (7.9%), infections (5.9%), organ dysfunctions (8.3%) and rare other complications (1.3%). No significant difference was found between the three surgical modalities, i.e. preoperative chemotherapy did neither increase the complication rate nor change the complication pattern. The biological meaning of primary tumour control is still unclear. However, a 40% local recurrence rate suggests an aggressive surgical attitude. Our study provides a basis that preoperative chemotherapy may be an effective tool to achieve complete removal of initially non-resectable primary tumours without increasing the complication rate.
 ...
PMID:The impact of preoperative chemotherapy on resectability of primary tumour and complication rate in metastatic neuroblastoma. 271 35

To evaluate the feasibility and clinical usefulness of immunocytochemical detection of bone marrow metastases in neuroblastoma, we studied bone marrow samples from patients undergoing intensive therapy, followed in the majority of cases by autologous bone marrow rescue. Two monoclonal antibodies were used in an indirect immunoenzymatic assay to test 384 samples collected from multiple bone marrow sites during 79 staging procedures in 48 patients. Of 578 immunocytochemical tests, 59 (10%) yielded non-evaluable results. Analysis by individual bone marrow sites showed an agreement between cytological and immunocytochemical examinations in 276 of 309 (89%) evaluable tests with 5 A7 and in 179 of 210 (85%) with UJ 13 A. Infiltration by neuroblastoma cells was reported in 9% of samples by cytology, in 6% by immunochemistry with 5 A7 and in 16% with 13 A. Analysis of results by staging demonstrated agreement between cytological examination and immunocytochemical detection with both monoclonal antibodies in 60 of 75 (80%) evaluable stagings. Bone marrow metastasis was detected by cytology in 22% of stagings, by immunochemistry with 5 A7 in 23%, with UJ 13 A in 25%. Detailed analysis of discordant results revealed that they were related partly to bone marrow sampling variability associated with focal and minimal metastasis of neuroblastoma cells. These data suggest the clinical usefulness of immunocytochemical detection as a complementary test to cytological examination for accurate evaluation of bone marrow infiltration in patients with disseminated neuroblastoma.
 ...
PMID:Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. 305 90

Eleven fine needle aspiration (FNA) biopsies were performed on seven children with neuroblastoma, including one patient with a congenital neuroblastoma and another with a peripheral neuroblastoma of the thoracopulmonary region. FNA cytology made the primary diagnosis of neuroblastoma in four of the seven cases. The other biopsies documented local recurrences and metastases to liver, lymph nodes, orbit and breast. The cytologic features included varying numbers of small primitive cells with scanty cytoplasm, poorly to well-formed pseudorosettes, cell processes, a fibrillary matrix and multinucleated ganglion cells. Five of the seven patients had electron microscopic (EM) examination of the FNA specimen, which in all cases confirmed the diagnosis. Batteries of immunoperoxidase stains were performed on all 11 aspirates with variable results. Staining for neuron-specific enolase was positive in four of the five neoplasms tested, although strongly positive in only three of the cases. Staining for neurofilament markers was positive in only two of five tumors. Studies for cytokeratin markers (AE1/3), low-molecular-weight cytokeratin (35BH11), hematopoietic markers (T29/33), immunoglobulin light chains and myoglobin were negative. One case was positive for vimentin. This study attests to the value of FNA cytology in suggesting a correct diagnosis of either primary, recurrent or metastatic neuroblastoma in children. Selective use of immunoperoxidase stains and EM on the aspirates may be of value.
 ...
PMID:Fine needle aspiration cytology of neuroblastoma, including peripheral neuroectodermal tumor, with immunocytochemical and ultrastructural confirmation. 328 19

Chemotherapy and surgery are both important for the treatment of neuroblastoma. The therapeutic indications depend upon the anatomic form of the tumor, but the quality of the surgical resection is most important. In metastatic neuroblastoma, the prognosis has recently been improved with massive chemotherapy, total body irradiation and bone marrow transplantation. Neuroblastoma occurring before one year of age has a particular position, because of its very good prognosis (90% survivals) but with frequent sequelae due to spinal cord compression. Possible improvements stemming from immunology, genetics and mass screening are discussed.
 ...
PMID:[Focus on neuroblastoma in 1987. 2: Treatment]. 331 64

Twenty cases of advanced neuroblastoma treated at the Pediatric Surgical Department of Chiba University from 1975 through 1985 were discussed. Cis-dichlorodiammineplatinum (CDDP) and VM-26 were administered to 7 patients with disseminated neuroblastoma resistant to treatment with cyclophosphamide, doxorubicin and vincristine. One complete remission, 4 partial remissions, and 2 minor responses were observed in our series. These results were far better than in our previous study, in which patients were treated with regimens containing cyclophosphamide, doxorubicin and vincristine. Several kinds of side effects were observed in children treated with CDDP. Vomiting occurred in all of them, and bone marrow toxicity was found in 5 among 7 patients. There was one case of severe nephrotoxicity caused by severe proximal tubular dysfunction with increased urinary loss of sodium, leading convulsion.
 ...
PMID:[Effectiveness of cis-dichlorodiammine-platinum in the treatment of advanced neuroblastoma]. 366 44

A metastatic neuroblastoma arose in a posterior mediastinal tumor that had been present for at least 52 years. The diagnosis of neuroblastoma was first made when the patient was 81 years of age from biopsy of a metastatic lesion to the femur and later from biopsy of the mediastinal mass.
 ...
PMID:Metastatic neuroblastoma after 52 years of dormancy. 366 32

In a patient with stage IV disseminated neuroblastoma treated by chemotherapy extensive cytogenetic investigations were performed on the residual primary tumour and bone marrow immediately before myeloablative treatment and autologous marrow rescue. Two abnormal clones both showing lp+, a characteristic abnormality of neuroblastoma, were detected in cells from the residual primary tumour, providing direct evidence of persisting viable tumour. Such investigations should be a routine part of the assessment of response to treatment in patients with neuroblastoma, and could be extended to others in whom "second look" surgery is performed.
 ...
PMID:Cytogenic investigations in the assessment of response to treatment in neuroblastoma. 369 71

Bone marrow examination at the time of diagnosis of neuroblastoma was performed in 48 new cases prior to instituting therapy. Bone marrow involvement by neuroblastoma was present in 20 patients (approximately 42%). In this study the trephine biopsy was a more reliable technique than marrow aspiration in establishing the presence of metastatic disease, but in a single case the trephine biopsy was negative with metastatic cells present in the aspirate. Myelofibrosis secondary to metastatic neuroblastoma was a frequent finding, being the predominant feature in 6 cases. Bone marrow involvement by neuroblastoma was usually associated with the presence of a primary adrenal tumor and occurred only infrequently with extra-adrenal primary origin. Bone marrow involvement was usually present at the time of presentation in case where the primary tumor was located in the adrenal gland.
 ...
PMID:Bone marrow changes in neuroblastoma. 376 7

The authors reviewed the case records of 1419 children with acute leukemia and other types of malignant disease involving the bone marrow to define the clinical and laboratory features associated with marrow necrosis as well as the prognostic significance of this complication. Only seven patients were found to have this abnormality: four with newly diagnosed acute lymphoblastic leukemia (ALL), one with relapsed ALL, and two with disseminated neuroblastoma. All patients presented with severe bone pain, bone tenderness, and fever. Levels of serum lactic dehydrogenase were uniformly increased, being especially high in patients with ALL. There was no evidence of severe infection or disseminated intravascular coagulation, complications that have been causally related to marrow necrosis. Four of the five children with ALL remain in complete remission for 10+ to 48+ months. Both patients with neuroblastoma are off therapy, in remission, for 9+ to 15+ months. In contrast to earlier reports, bone marrow necrosis does not appear to confer a poor prognosis in children with malignancy.
 ...
PMID:Bone marrow necrosis in children with malignant disease. 386 Dec 29

Monoclonal antibody (A 2 B 5) was raised against chick neural retina cells by Eisenbarth et al. We have studied, exclusively, A 2 B 5 for the immunological approach, and the following results were obtained. A 2 B 5 was shown to be IgG 2a subclass and reacted with all human neuroblastoma cell lines, NBGOTO, NB 1, TN-1 and C-NB1, in vitro by the 51Cr release cytotoxicity assay, but did not have cytotoxic activity for other tumor cell lines, C-1300 (A/J mouse neuroblastoma cell line), S1509a (A/J mouse induced sarcoma by methylcholanthrene) and P 39 (human malignant melanoma cell line). A 2 B 5 was titrated against constant numbers of human neuroblastoma cell lines. In the next experiment, detection of metastatic neuroblastoma cells in bone marrow, specimen and human neuroblastoma cell lines was undertaken by indirect immunofluorescence using A 2 B 5. All were visualized with binding A 2 B 5, and immunofluorescence could be seen on a clump of tumor cells binding A 2 B 5. Thus, A 2 B 5 may be particularly useful reagent for the diagnosis of bone metastasis of human neuroblastoma.
 ...
PMID:[Analysis of tumor antigens and clinical applications of monoclonal antibody (A 2 B 5) for neuroblastoma]. 388


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>